Axatilimab misses MAXPIRe phase II endpoint; Syndax ends planned development in pulmonary fibrosis
Published in Diseases!, Drugs development & discovery, Immunology.
Publication date: October 13, 2026.
Syndax announced on October 12 that its phase II MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint. The company does not plan further development of axatilimab for this indication.
MAXPIRe enrolled 145 patients across 62 sites in 14 countries. In this randomized, double-blind, placebo-controlled study, participants received axatilimab 0.3 mg/kg or placebo every two weeks in a 2:1 allocation, stratified by background antifibrotic treatment.
The primary endpoint was the annualized decline in forced vital capacity, a measure of lung function. The annualized estimate was derived from measurements collected over 26 weeks; it was not a full year of observed follow-up.
The company reported no new safety signals and tolerability comparable to placebo. Ongoing studies in chronic graft-versus-host disease continue separately.
Limits: this is a company topline disclosure, without numerical between-group FVC results, confidence intervals or a detailed peer-reviewed analysis. Failure of the primary endpoint limits support for this regimen in pulmonary fibrosis; it does not determine outcomes in other diseases.
Source: Syndax’s MAXPIRe announcement, October 12, 2026.